Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03758989 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Jun 1, 2026 → Dec 1, 2026
See other at-risk trials from University of Rochester

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jun 1, 2026 to Dec 1, 2026
    • Eligibility criteria expanded, about 12 words
  2. Primary completion date: Jun 1, 2025 to Jun 1, 2026v8
  3. Primary completion date: Jun 1, 2024 to Jun 1, 2025
    • Study completion date: Jun 1, 2026 to Jun 1, 2027
    v7
  4. Re-verified, no change to tracked fieldsv6
  5. Primary completion date: Jun 1, 2022 to Jun 1, 2024
    • Study completion date: Jun 1, 2024 to Jun 1, 2026
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. 2 versions Re-verified since Sep 1, 2020, no change to tracked fieldsv3-v4
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Start date changed from estimate of Jan 1, 2019 to May 8, 2019
    • Study sites: 0 to 1
    • Primary completion date: Jan 1, 2022 to Jun 1, 2022
    • Study completion date: Jan 1, 2024 to Jun 1, 2024
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The overarching goals of this study are to measure levels of circulating tumor DNA (ctDNA) in patients with early stage diffuse large B cell lymphoma (DLBCL), to assess the change in ctDNA during treatment in order to prospectively identify markers of treatment failure, and to use ctDNA as a future tool for response adapted therapy.
Trial Details
NCT Number NCT03758989
Lead Sponsor University of Rochester
Conditions
(from sponsor)		 DLBCL
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov